1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muńoz J, Bosch FX, de Sanjosé S. ICO Information Centre on HPV and Cancer (HPV Information Centre) Human Papillomavirus and Related Diseases in the World. Summary Report 15 December. 2016. Google Scholar

  2. World Health Organization. International agency for research in cancer, 2012. Accessed 6th May 2016 .

  3. Mosha D, Mahande M, Ahaz J, Mosha M, Njau B, Kitali B, Obure J. Factors associated with management of cervical cancer patients at KCMC Hospital, Tanzania: a retrospective cross-sectional study. Tanzania Journal of Health Research. 2009; 11(2): 70-4. PubMed | Google Scholar

  4. Forhan SE, Godfrey CC, Watts DH, Langley CL. A systematic review of the effects of visual inspection with acetic acid, cryotherapy and loop electrosurgical excision procedures for cervical dysplasia in HIV-infected women in low-and middle- income countries. J Acquir Immune Defic Syndrome. 2015; 68(3); 350-6. PubMed | Google Scholar

  5. World Health Organisation.Globocan 2012. Accessed on 25 April 2017

  6. Centres for disease control and prevention. National centre for infectious diseases division of HIV/AIDS. 1993 Revised Classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Accessed 12 December 2014

  7. Ajenifuja KO, Gage JC, Adepiti AC, Wentzensen N, Eklund C, Reilly M, Hutchinson M, Burk RD, Schiffman M. A population based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria. Int J Gynecol Cancer. 2013; 23(3): 507-512. PubMed | Google Scholar

  8. Globocan. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer (IARC); 2012. Accessed on 6 May 2017.

  9. Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008; 1(1): 2-10. PubMed | Google Scholar

  10. World Health Organisation. Annual WHO/UNICEF Joint reporting form (July 2015) Geneva Immunisation, Vaccines and Biologicals, World Health Organisation. Accessed on 23 February 2017.

  11. African coalition on maternal, newborn and child health. Africa cervical cancer multi indicator incidence and mortality scorecard. WHO. 2014. Accessed on 20th Feb 2017.

  12. Chokunonga E, Borok MZ, Chirenje ZM, Makunike-Mutasa R, Ndlovu N, Nyakabau AM, Vuma S. Zimbabwe National Cancer registry: 2014 Annual Report: pattern of cancer in Zimbabwe. Accessed on 5 April 2017.

  13. Information Centre for Cancer. Human papillomavirus in Zimbabwe report. Accessed on 31 January 2017

  14. Chin'ombe N, Sebata NL, Ruhanya V, Matarira HT. Human Papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe. Infect Agent Cancer. 2014; 9(16): 1-4. PubMed | Google Scholar

  15. UNAIDS. United Nations AIDS. Accessed on 5 February 2017.

  16. Sachdeva RK, Sharma A, Singh S, Varma S. Spectrum of AIDS defining and non-AIDS defining malignancies in North India. Indian J Med Res. 2016; 143(1): S129-135. PubMed | Google Scholar

  17. International Agency for Research on Cancer. Information Centre for Human Papillomavirus and cancer. Accessed on 5 June 2017

  18. World Health Organization (WHO). Comprehensive cervical cancer prevention and control: a healthier future for girls and women 2013. Accessed 6 July 2015.

  19. Finocchario-Kessler S, Wexler C, Maloba M, Mabachi N, Ndikum-Moffor F, Bukusi E. Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective.BMC Womens Health. 2016; 16(29): 1-25. PubMed | Google Scholar

  20. WHO. Human Papillomavirus laboratory manual. Accessed on 16 may 2017.

  21. Maine D, Hurlburt S, Greeson D. Cervical cancer prevention in the 21st century: Cost is not the only issue.Am J Public Health. 2011; 101(9): 1549-55. PubMed | Google Scholar

  22. World Health Organisation. ICO Information of HPV and Cancer: World. Accessed on 6 June 2017.

  23. St Alberts mission hospital. St Alberts mission hospital viac annual report. Accessed on 8 May 2017

  24. Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: Application to implementation. Vaccines (Basel). 2015 May 20; 3(2): 408-19. PubMed | Google Scholar

  25. Castellsague X, Paavonen J, Jaisamrarn U, Wheeler CM, Skinner SR. HPV PATRICIA Study Group: risk of first cervical HPV infection and pre-canerous lesions after onset of sexual activity:analysis of women in the control arm of the randomised, control PATRICIA trial. BMC infect Dis. 2014; 14: 551. PubMed | Google Scholar

  26. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Baileyy A, Young LS. High incidence of cervical cancer human papillomavirus infection in women during their first sexual relationship. BJOG Int J Obstet Gynaecol. 2002; 109(1): 96-8. PubMed | Google Scholar

  27. Kjaer SK, Chackerlan B, van den Brule AJ, Svare EI, Paull G, Walbomers JM. High-risk human papillomavirus is sexually transmitted:evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2001; 10(2): 101-6. PubMed | Google Scholar

  28. World Health Organisation. Weekly epidemiological record. Relevé épidémiologique hebdomadaire. Accessed on 24 April 2017

  29. Fairley G, Hocking J, Chen M, Donovan, Bradshaw, C. Rapid decline in warts after national qudrivalent HPV vaccine program. The 25th international papillomavirus conference. May 8-14; 2009: Malmo, Sweden. Google Scholar

  30. Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, Garland, SM. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine. 2008; 26(10): K68-75s. PubMed | Google Scholar

  31. Public Health England. Human Papillomavirus (HPV) Vaccine coverage in England, 2008/09 to 2013/14: A review of the full six years of the three-dose schedule. Accessed on 1 June 2017.

  32. Health Policy Monitor. HPV vaccination in Switzerland: where are we? Accessed on 1 June 2017

  33. Boiron L, Joura E, Largaeron N, Prager B, Uhari M. Estimating the cost-effectiveness profile of a universal vaccination programmee with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016; 16(153): 1483-5. PubMed | Google Scholar

  34. Public Health Association of South Africa. Implementation of HPV vaccination in South Africa. 2015. Accessed on 1 June 2017

  35. Grover S, Raesima M, Bvochora-Nsingo M, Chiyapo SP, Balang D, Tapela N, Balogun O, Kayembe MKA, Russell AH, Monare B, Tanyala S, Bhat Jailakshmi B, Thipe K, Mchunga M, Mayisela S, Kiziro B, Ho-Foster A, Gaolebale BE, Baolebale PA, Efstathiou JA, Dryden-Peterson S, Zetola N, Hahn SM, Robertson ESm Lin LL, Morroni C, Ramogola-Masire D. Cervical cancer in Botswana: current state and future steps for screening and treatment programs. Frontiers in Oncology. 2015; 5(239): 1-5. PubMed | Google Scholar

  36. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of evidence. Vaccine 2009. Accessed on 31 January 2017

  37. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccinations in cervical cancer prevention. Gynaecologic Oncology. 2008; 110(3): 18-25. PubMed | Google Scholar

  38. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie SJ. Health and economic impact of HPV16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2012; 130 (11): 2672-84. PubMed | Google Scholar

  39. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for Human Papillomavirus vaccination- Updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report. 2016; 65(49): 1405-1408. PubMed | Google Scholar

  40. Paul KT. 'Saving lives': adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Social Science and Medicine. 2016; 153. Accessed on 1 June 2017

  41. Mangoma JF, Chirenje MZ, Chimbari MJ, Chandiwana SK. An assessment of rural women's knowledge, constraints and perceptions on cervical cancer screening: the case of two districts in Zimbabwe. Afr J Reprod Health. 2006; 10(1): 91-103. PubMed | Google Scholar

  42. Song YJ. Knowledge, attitude and beliefs in cervical cancer prevention and HPV vaccination among college youths in Taiwan- a gender-based approach. Accessed on 3 March 2017 2010.

  43. Brown B, Folayan M. Barriers to the uptake of human papilloma virus vaccine in Nigeria: a population in need. Niger Med J. 2015; 56(4): 301. PubMed | Google Scholar

  44. Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatmen of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008; 29(4): 345-9. PubMed | Google Scholar

  45. World Heaith Organisation. World Health Organisation Regional Office for Africa: Cervical cancer common amongst African women. Accessed on 3 April 2017

  46. Fallala MS, Mash R. Cervical cancer screening: safety, acceptability and feasibility of a single-visit approach in Bulawayo, Zimbabwe. Afr J Prm Health Care Fam Med. 2015; 7(1): 742-9. PubMed | Google Scholar

  47. Chirenje ZM, Rusakaniko S, Kirumbi L, Ngwalle EW, Makuta-Tlebere PP, Kaggwa S, Mpanju-Shumbusho W, Makoae L. Situation analysis for cervical cancer diagnosis and treatment in East, Central and Southern African countries. World Health Organisation. 2001; 79(2): 127-132. PubMed | Google Scholar

  48. Eke NO, Eke CO, Nwosu BO, Akabuike JC, Ezeigwe CO. Okoye SC Cervical cancer screening by female workers in South East Nigeria. African Journals Online. 2006; 1-5. Google Scholar

  49. Albrow R, Kitchener H, Gupta N, Desai M. Cervical screening in England: the past, present and future. Cancer Cytopathology. 2012; 120(2): 87-96. PubMed | Google Scholar

  50. Thistle PJ, Chirenje Z M. Cervical cancer screening in rural population of Zimbabwe. Centr Afr J Med. 1997; 43(9): 246-51. PubMed | Google Scholar

  51. Chirenje ZM, Akino V. Screening for cervical cancer: experience from the Colposcopy Clinic at Harare Hospital. Cent Afr J Med. 1993; 39(11): 222-4. PubMed | Google Scholar

  52. Mafuva C, Djarova T, Matarira HT. Influence of combined oral contraceptives on the onsent of cervical intraepithelial neoplasia. Afr J Health Sci. 2002; 9(3-4): 129-37. PubMed | Google Scholar

  53. Rosser JI, Hamisi S, Njoroge B, Huchko MJ. Barriers to cervical cancer screening in rural Kenya: perspectives from a provoder survey. J Community Health. 2015; 40(4): 756-61. PubMed | Google Scholar

  54. Moyo IM, Koni NP, Makunike B, Hipshman J, Makaure HK, Gumbo N. Evaluation of cervical cancer screening programme in the Harare City Health Department, Zimbabwe. Centr Afr J Med. 1997; 43(8): 223-5. PubMed | Google Scholar

  55. Mbizvo EM, Msuya SE, Stray-Pedersen B, Chirenje MZ, Hussain A. Cervical dyskaryosis among women with and without HIV: prevalence and risk factors. Int J of STDs and AIDS. 2005; 16: 789-93. PubMed | Google Scholar

  56. Abotchie PN, Shokar NK. Cervical cancer screening among college students in Ghana: knowledge and health beliefs. Int J Gynaecol Cancer. 2010; 19(3): 412-16. PubMed | Google Scholar

  57. CDC. STD treatment guidelines. Accessed on 5 June 2017

  58. Sellors J, Camacho Carr K, Bingham A, Winkler J. Course in Visual Methods for Cervical Cancer Screening: visual Inspection With Acetic Acid and Lugol's Iodine. Seattle, WA; PATH. 2004. Google Scholar

  59. Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv. 1999; 54(2): 131-137. PubMed | Google Scholar

  60. World Health Organization. World Health Organization guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. Geneva: World Health Organization. Accessed on 17 June 2013.

  61. Kitchener HC, Syonds P. Detection of cervical intraepithelial neoplasia in developing countries. Lancet. 1999; 353 (9156): 856-7. PubMed | Google Scholar

  62. Sherigar B, Dalal A, Dardi G, Pujar Y, Dhumale H. Cervical cancer screening by visual inspection with acetic-interobserver variability between nurse and physician. Asian Pac J Cancer Prev. 2010; 11(3): 619-22. PubMed | Google Scholar

  63. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010; 102(20): 1557-67. PubMed | Google Scholar

  64. Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, Parkin, DM. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Multicenter Study Int J Cancer. 2004; 110(6): 907-913. PubMed | Google Scholar

  65. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Practice Guideline Am J Clin Pathol. 2012; 137(4): 516-542. PubMed | Google Scholar

  66. Cervical cancer prevention fact sheet. Ten key findings and recommendations for effective cervical cancer screening and treatment programs. Accessed on 25th Spril 17.

  67. Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016; 37(4): 278-85. PubMed | Google Scholar

  68. International Federation of Gynaecology and Obstetrics. Global guidance for cervical cancer prevention and control. Accessed on 25 April 2017.

  69. Singla S, Mathur S, Kriplani A, Agarwal N, Garg P, Bhatla N. Single visit approach for management of cervical intraepithelial neoplasia by visual inspection & loop electrosurgical excision procedure. Indian J Med Res. 2012; 135(5): 614-20. PubMed | Google Scholar

  70. Chumworathayi B, Blumenthal PD, Limpaphayom KK, Kamsa-Ard S, Wongsena M, Supaatakorn P. Effect of single-visit VIA and cryotherapy cervical cancer prevention program in Roi Et, Thailand: a preliminary report. J Obstet Gynaecol Res. 2010; 36(1): 79-85. PubMed | Google Scholar

  71. Khuhaprema T, Attasara P, Srivatanakul P, Sangrajrang S, Muwonge R, Sauvaget C, Sankaranarayanan, R. Organization and evolution of organized cervical cytology screening in Thailand. Int J Gynaecol Obstet. 2012; 118 (2): 107-11. PubMed | Google Scholar

  72. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010; 21(10): 1693-700. PubMed | Google Scholar

  73. Sankaranarayanan R. 'See-and-treat' works for cervical cancer prevention: what about controlling the high burden in India. Int J Med Res. 2012; 135(5): 576-9. PubMed | Google Scholar

  74. Hasahya OT, Berggren V, Sematimba D, Nabirye RC, Kumakech E. Beliefs, perceptions and health seeking behavious in relation to cervical cancer: a qualitative study among women in Uganda following completion of an HPV vaccination campaign. Global Health Action. 2016; 9(29336): 1-9. PubMed | Google Scholar

  75. Chirenje ZM, Rusakaniko S, Kirumbi L, Ngwalle EW, Makuta-Tlebere P, Kaggwa S, Mpanju-Shumbuso W, Makoae L. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ. 2001; 79(2): 17-32. PubMed | Google Scholar

  76. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010; 102: 1557-67. PubMed | Google Scholar

  77. Chirenje ZM, Rusakaniko S, Akino V, Munjoma M, Mlingo M. Effect of HIV disease in treatment outcome of cervical squamous intraepithelial lesions among Zimbabwean women. J Low Genit Tract Dis. 2003; 7(1): 16-21. PubMed | Google Scholar

  78. Cho H, Kim JH. Treatment of the patients with abnormal cervical cytology: a 'see-and-treat' versus three-step strategy. J Gynecol Oncol. 2009; 20(3): 164-8. PubMed | Google Scholar

  79. Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A review of cervical cancer patients presenting in Harare and Parirenyatwa Hospitals in 1998. Centr Afr J Med. 2000; 46(10): 264-7. PubMed | Google Scholar

  80. Ndlovu N, Kambarami R. Factors associated with tumour stage at presentation in invasive cervical cancer. Centr Afr J Med. 2003; 49(9-10): 107-11. PubMed | Google Scholar

  81. Texas Oncology. cancer. Accessed on 7 February 2017.

  82. Kadzatsa W, Chokunonga E. The Status and Challenges of Cancer Care in Zimbabwe. Accessed on 6 February 2017

  83. Khumalo T, Maasdorp V. The island hospice model of palliative care. eCancer Medical Science. 2016; 10(654): 1-7. PubMed | Google Scholar